Molecular testing is being emphasized in the treatment of non-small-cell lung cancer. Various studies and data, including those on targeted drugs and specific genetic mutations such as ROS1, EGFR, and HER2, highlight the importance of molecular testing in informing treatment decisions. The role of molecular testing in lung cancer is being explored from multiple angles, including its potential to reduce recurrence and improve outcomes.